Buchumschlag

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Jian Wang, Tao Fan, Shaoqiu Zhang, Chao Wu, Rui Huang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
von: Chen‐Pi Li, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B
von: Jing Li, et al.
Veröffentlicht: (2024)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
von: WenXian OuYang, et al.
Veröffentlicht: (2024)

Higher end‐of‐treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg‐negative chronic hepatitis B patients stopping antivirals
von: Yen‐Chun Liu, et al.
Veröffentlicht: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
von: Jiamei Wang, et al.
Veröffentlicht: (2024)

Letter: Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in chronic hepatitis B virus infection
von: Jianrong Li, et al.
Veröffentlicht: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
von: Eiichi Ogawa
Veröffentlicht: (2024)

Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection
von: Na‐Ling Kang, et al.
Veröffentlicht: (2024)

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
von: Hye Won Lee, et al.
Veröffentlicht: (2024)

Favourable Prognosis of Patients With Untreated HBeAg‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL
von: Jian Wang, et al.
Veröffentlicht: (2024)

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials
von: Maria Buti, et al.
Veröffentlicht: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
von: Lisa Sandmann, et al.
Veröffentlicht: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
von: Rui Huang, et al.
Veröffentlicht: (2025)

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
von: Haibo Jing, et al.
Veröffentlicht: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
von: Zhuo Li, et al.
Veröffentlicht: (2024)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
von: Yuxin Chen, et al.
Veröffentlicht: (2024)

Letter: Resmetirom for treatment of MASH with children and adolescents
von: Yong‐Hai Zhou, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
von: Mingsi Zhang, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis
von: Yu Liu, et al.
Veröffentlicht: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
von: Xiaojuan Liu, et al.
Veröffentlicht: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
von: Yuxin Chen, et al.
Veröffentlicht: (2025)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
von: Elena Vargas‐Accarino, et al.
Veröffentlicht: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
von: Fang Yan, et al.
Veröffentlicht: (2024)

Letter: ‘Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation’
von: You‐Jian Xu, et al.
Veröffentlicht: (2024)

Letter: Social work and clinical synergy—Optimising health interventions for elderly DGBI populations
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
von: Min Wu, et al.
Veröffentlicht: (2024)

Letter: Over‐the‐scope clips in patients at high risk of rebleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone? Authors'reply
von: Kai Song, et al.
Veröffentlicht: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis
von: Carolyn Singleton, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
von: Elliot B. Tapper, et al.
Veröffentlicht: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
von: Ivan Arcari, et al.
Veröffentlicht: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
von: Jung Eun Park, et al.
Veröffentlicht: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Rong‐Xiang Ng, et al.
Veröffentlicht: (2025)